OncoCyte Statistics

Share Statistics

OncoCyte has 28.6M shares outstanding. The number of shares has increased by 113.84% in one year.

Shares Outstanding	28.6M
Shares Change (YoY)	113.84%
Shares Change (QoQ)	0%
Owned by Institutions (%)	0.17%
Shares Floating	7.75M
Failed to Deliver (FTD) Shares	22,027
FTD / Avg. Volume	28.96%

Short Selling Information

The latest short interest is 288.99K, so 0% of the outstanding shares have been sold short.

Short Interest	288.99K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.68

Valuation Ratios

The PE ratio is -0.51 and the forward PE ratio is -3.4. OncoCyte's PEG ratio is -0.02.

PE Ratio	-0.51
Forward PE	-3.4
PS Ratio	16.54
Forward PS	20.8
PB Ratio	-2.53
P/FCF Ratio	-1.47
PEG Ratio	-0.02

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for OncoCyte.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.62, with a Debt / Equity ratio of -0.3.

Current Ratio	1.62
Quick Ratio	1.56
Debt / Equity	-0.3
Debt / EBITDA	-0.06
Debt / FCF	-0.17
Interest Coverage	-726.68

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$40.89K
Profits Per Employee	$-1.32M
Employee Count	46
Asset Turnover	0.05
Inventory Turnover	2.78

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 8.11% in the last 52 weeks. The beta is 0.99, so OncoCyte's price volatility has been higher than the market average.

Beta	0.99
52-Week Price Change	8.11%
50-Day Moving Average	3.03
200-Day Moving Average	2.82
Relative Strength Index (RSI)	44.21
Average Volume (20 Days)	76,061

Income Statement

In the last 12 months, OncoCyte had revenue of 1.88M and earned -60.66M in profits. Earnings per share was -4.66.

Revenue	1.88M
Gross Profit	740K
Operating Income	-61.04M
Net Income	-60.66M
EBITDA	-59.02M
EBIT	-60.58M
Earnings Per Share (EPS)	-4.66

Full Income Statement

Balance Sheet

The company has 8.64M in cash and 3.66M in debt, giving a net cash position of 4.97M.

Cash & Cash Equivalents	8.64M
Total Debt	3.66M
Net Cash	4.97M
Retained Earnings	-350.54M
Total Assets	60.36M
Working Capital	26.58M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -20.71M and capital expenditures -516K, giving a free cash flow of -21.23M.

Operating Cash Flow	-20.71M
Capital Expenditures	-516K
Free Cash Flow	-21.23M
FCF Per Share	-1.62

Full Cash Flow Statement

Margins

Gross margin is 39.34%, with operating and profit margins of -3245.14% and -3225.04%.

Gross Margin	39.34%
Operating Margin	-3245.14%
Pretax Margin	-3225.04%
Profit Margin	-3225.04%
EBITDA Margin	-3137.43%
EBIT Margin	-3245.14%
FCF Margin	-1128.6%

Dividends & Yields

OCX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for OCX is $4.25, which is 32.8% higher than the current price. The consensus rating is "Buy".

Price Target	$4.25
Price Target Difference	32.8%
Analyst Consensus	Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on Jul 25, 2023. It was a backward split with a ratio of 1:20.

Last Split Date	Jul 25, 2023
Split Type	backward
Split Ratio	1:20

Scores

Altman Z-Score	-9.8
Piotroski F-Score	5

OncoCyte Corporation (OCX)